Skip to the page

Data / Drug companies / Siegfried Barbera, SL

Siegfried Barbera, SL: 12 products in the FDA NDC directory, labeler code 81719

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Siegfried Barbera, SL (labeler code 81719) lists 12 products in the FDA National Drug Code Directory. By type: 12 drugs for further processing. Its main marketing category is drugs for further processing. The newest product started marketing on December 13, 2021.

The request: Watch Siegfried Barbera, SL (FDA labeler code 81719): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
81719
Products in commercial distribution
12
Packages
12
Finished drugs by generic name
0
Prescription products
0
Over the counter products
0
Started marketing in the last 12 months
0
Earliest marketing start
April 4, 2009
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Drugs for further processing12100%

Products by type

TypeProductsShare
Drugs for further processing12100%

Dosage forms

Dosage formProductsShare
Tablet, film coated975%
Capsule216.7%
Tablet18.3%

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Pazopanib hydrochloride81719-017TabletDrugs for further processingDecember 13, 2021
Eltrombopag olamine81719-004Tablet, film coatedDrugs for further processingAugust 22, 2016
Eltrombopag olamine81719-005Tablet, film coatedDrugs for further processingMay 24, 2016
Dabrafenib mesylate81719-015CapsuleDrugs for further processingApril 12, 2016
Eltrombopag olamine81719-006Tablet, film coatedDrugs for further processingApril 7, 2016
Dabrafenib mesylate81719-016CapsuleDrugs for further processingApril 1, 2016
Eltrombopag olamine81719-007Tablet, film coatedDrugs for further processingApril 1, 2016
Amlodipine, valsartan and hydrochlorothiazide81719-014Tablet, film coatedDrugs for further processingApril 4, 2009
Amlodipine, valsartan and hydrochlorothiazide81719-013Tablet, film coatedDrugs for further processingApril 4, 2009
Amlodipine, valsartan and hydrochlorothiazide81719-012Tablet, film coatedDrugs for further processingApril 4, 2009
Amlodipine, valsartan and hydrochlorothiazide81719-011Tablet, film coatedDrugs for further processingApril 4, 2009
Amlodipine, valsartan and hydrochlorothiazide81719-010Tablet, film coatedDrugs for further processingApril 4, 2009

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.